Your fact-checks will appear here
Medical device company
Urinary incontinence is treated with a wide spectrum of options: conservative care (pelvic floor muscle training, bladder training), medications and injections (antimuscarinics, onabotulinumtoxinA/Bot...
Reported links between Elon Musk and a urinary‑incontinence device in news and social posts point to neuromodulation implants developed by established medtech firms—primarily Neuspera and Medtronic—ra...
The available evidence shows ; reporting about Gates concerns investments in a separate company, Renmatix, which works on converting biomass into cellulosic sugars for industrial uses, not the nutriti...
Bill Gates has no documented personal investment in Sugarwise, the U.K.-based sugar-certification group, nor is there evidence he personally funded SugarWise the diabetes app; public reports instead l...
Available reporting in the search results treats “Neurocept” as a brain-health supplement newly marketed in 2025 and compares it broadly to other cognitive-support products . The dataset does not pres...
Over the past five years, two interlocking forces have driven patient access to sacral neuromodulation (SNM): a flurry of FDA device approvals that expanded the available implants and indications, and...
Neurotech’s competitive landscape is crowded and bifurcated between large medtech incumbents that sell approved implants and broad service networks (e.g., Medtronic, Abbott, Boston Scientific) and a f...
Current standard therapies for urinary incontinence include behavioral/pelvic‑floor training, medications (antimuscarinics, beta‑3 agonists), onabotulinumtoxinA injections, nerve stimulation (sacral a...
Multiple device trials — from implantable tibial neuromodulation (eCoin, Altaviva) to digital pelvic‑floor therapeutics and traditional slings/sphincters — are active and have published trial data or ...
No regulatory agency record in the supplied reporting ties any formal approval or investigation to “Musk’s urinary incontinence therapy.” Coverage instead discusses approved devices and drugs for urge...
Existing treatments for urinary incontinence range from conservative measures (pelvic floor training and bladder retraining) to drugs, injectable bulking agents, slings and sacral neuromodulation; sac...
Neurocept appears in commercial supplement/product listings and on its own websites claiming manufacture in an “FDA-registered” or “FDA-approved” facility, but available reporting and regulatory datab...
Available reporting and Neuralink’s own public materials show the company focusing its early human trials on restoring function for people with paralysis and other central nervous system targets — not...
Available reporting does not present head‑to‑head clinical studies that compare the supplement/product "GlucoSense" directly with standard continuous glucose monitors (CGMs). GlucoSense appears in com...
The main manufacturers of implantable sacral neuromodulation devices for urinary incontinence are Medtronic (InterStim) and Axonics (Axonics SNM), which are repeatedly identified in clinical literatur...
No reputable medical organizations in the provided reporting are shown to endorse SugarWise as a diabetes treatment; SugarWise’s own marketing describes it as a dietary supplement that “should not rep...
Neurocept is not mentioned in the provided search results, so available sources do not describe its technology, clinical data, or regulatory status (not found in current reporting). The broader neurom...